Payment overview · 2025
General Payments
$388.95
15 reported records · 8 companies
Healthcare provider profile · identity verified
Eleonora Fedonenko, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1790721850
Verified facts
What the public records show
CMS Open Payments records show Eleonora Fedonenko, M.D. received $388.95 in general payments during 2025 across 15 reported records.
Aimmune Therapeutics, Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Trulance, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Zenpep by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $147.33 | 37.9% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.96 | 22.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.24 | 9.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.97 | 8.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.72 | 7.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.16 | 6.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.08 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.49 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.95 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $147.33 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.96 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 87 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
365 | 50 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
136 | 12 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 638 | 75 |
| Gabapentin | Gabapentin | 608 | 82 |
| Famotidine | Famotidine | 586 | 70 |
| Dexlansoprazole Dr | Dexlansoprazole | 512 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 61 |
| Nebivolol Hcl | Nebivolol Hcl | 450 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 45 |
| Linzess | Linaclotide | 365 | 50 |
| Ezetimibe | Ezetimibe | 339 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 330 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 314 | 36 |
| Febuxostat | Febuxostat | 308 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 294 | 33 |
| Sertraline Hcl | Sertraline Hcl | 255 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 41 |
| Lidocaine | Lidocaine | 229 | 30 |
| Metformin Hcl | Metformin Hcl | 222 | 28 |
| Montelukast Sodium | Montelukast Sodium | 215 | 23 |
| Vascepa | Icosapent Ethyl | 209 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 180 | 19 |
| Celecoxib | Celecoxib | 172 | 19 |
| Clonidine Hcl | Clonidine Hcl | 171 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 28 |
| Tramadol Hcl | Tramadol Hcl | 170 | 44 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 169 | 20 |
| Mirtazapine | Mirtazapine | 166 | 18 |
| Trazodone Hcl | Trazodone Hcl | 162 | 27 |
| Memantine Hcl | Memantine Hcl | 159 | 21 |
| Ozempic | Semaglutide | 155 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 153 | 25 |
| Pitavastatin Calcium | Pitavastatin Calcium | 148 | 23 |
| Captopril | Captopril | 143 | 14 |
| Synthroid | Levothyroxine Sodium | 136 | 12 |
| Carvedilol | Carvedilol | 134 | 18 |
| Clonidine | Clonidine | 131 | 15 |
| Omeprazole | Omeprazole | 129 | 19 |
| Repatha Sureclick | Evolocumab | 128 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 14 |
| Meclizine Hcl | Meclizine Hcl | 126 | 18 |
| Losartan Potassium | Losartan Potassium | 125 | 15 |
| Eliquis | Apixaban | 123 | 17 |
| Furosemide | Furosemide | 121 | 14 |
| Telmisartan | Telmisartan | 114 | 12 |
| Januvia | Sitagliptin Phosphate | 113 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 113 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 22 |
| Ketoconazole | Ketoconazole | 111 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 13 |
| Allopurinol | Allopurinol | 109 | 15 |
| Glimepiride | Glimepiride | 98 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 96 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 96 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 95 | suppressed |
| Meloxicam | Meloxicam | 92 | 11 |
| Myrbetriq | Mirabegron | 90 | 13 |
| Atenolol | Atenolol | 87 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 87 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | suppressed |
| Creon | Lipase/Protease/Amylase | 82 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | suppressed |
| Praluent Pen | Alirocumab | 81 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 16 |
| Prednisone | Prednisone | 71 | 32 |
| Bupropion Xl | Bupropion Hcl | 70 | suppressed |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 33 |
| Vilazodone Hcl | Vilazodone Hcl | 67 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Baclofen | Baclofen | 63 | 12 |
| Edarbi | Azilsartan Medoxomil | 63 | suppressed |
| Potassium Chloride | Potassium Chloride | 61 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 60 | suppressed |
| Fenofibrate | Fenofibrate | 60 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 20 |
| Nexium | Esomeprazole Magnesium | 59 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 45 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Finasteride | Finasteride | 54 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 20 |
| Diclofenac Epolamine | Diclofenac Epolamine | 53 | suppressed |
| Lorazepam | Lorazepam | 53 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 51 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Gemfibrozil | Gemfibrozil | 50 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 14 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | suppressed |
| Rivastigmine | Rivastigmine | 44 | suppressed |
| Livalo | Pitavastatin Calcium | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Azithromycin | Azithromycin | 40 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Clotrimazole | Clotrimazole | 34 | suppressed |
| Lisinopril | Lisinopril | 34 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 32 | suppressed |
| Trulance | Plecanatide | 32 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Dexilant | Dexlansoprazole | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Uloric | Febuxostat | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Ramelteon | Ramelteon | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 18 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dayvigo | Lemborexant | 15 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Mupirocin | Mupirocin Calcium | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lexapro | Escitalopram Oxalate | 12 | suppressed |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.95 · 15 records | Aimmune Therapeutics, Inc. | BOTOX, Kerendia, LEQVIO, Ozempic, TRULANCE, VOQUEZNA, ZENPEP, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error